Kyverna outlined a registrational path for KYV-101 in generalized myasthenia gravis (MG), converting its KYSA-6 study into a Phase 2/3 program following alignment with the FDA, to target Phase 3 enrollment by year-end 2025. The Phase 3 portion will randomize approximately 60 adults 1:1 to a single infusion of KYV-101 versus continuation of standard of care, with co-primary endpoints of MG-ADL and QMG change from baseline at 24 weeks. Key secondary measures include MGC, the proportion achieving at least a 3-point reduction in MG-ADL, attainment of Minimum Symptom Expression, and remaining off immunosuppressants. Patients initially assigned to the standard of care will have the option to crossover to KYV-101. The company also highlighted longer-term follow-up from compassionate-use recipients in MG and stiff-person syndrome (SPS). It reiterated its intent to pursue the first FDA approval in SPS, where no approved therapies exist.
The operational and statistical choices suggest a speed-optimized strategy based on an anticipated large effect size. A 60-patient, open-label, superiority design with a 24-week primary assessment window trades blinding and long-term comparative data for a compact enrollment target and pragmatic execution. Excluding concomitant background immunosuppression in the KYV-101 arm is a deliberate bid to demonstrate disease modification and drug-free remission; it also raises the bar on safety oversight during tapering and heightens the importance of rescue protocols. Allowing crossover improves recruitment but may blunt longer-term comparative readouts and shift the evidentiary burden to the early, robust separation of MG-ADL and QMG curves.
For sites, this moves CAR T workflows into neuromuscular clinics, demanding tight integration with established cell therapy centers. Apheresis logistics, lymphodepletion management, inpatient monitoring for CRS and neurotoxicity, and long-term immunoglobulin management must be layered onto neurology operations that are not traditionally configured for cell therapy. Screening and washout requirements could concentrate enrollment at academic centers with both neuromuscular expertise and CAR T infrastructure, potentially slowing accrual and narrowing the patient mix. Heterogeneity in the control arm—ranging from traditional agents to complement inhibitors—adds operational and analytic complexity, requiring careful stratification and adjudication.
For sponsors and CROs, the design underscores a broader pivot of CD19-directed cell therapy into autoimmune neurology, with trial conduct challenges closer to oncology than to typical MG studies. Patient-reported outcomes, such as MG-ADL, are susceptible to expectation bias in open-label settings; therefore, QMG and MGC will require rigorous rater training to preserve signal quality. Competitors in MG built around chronic FcRn or complement blockade face a differentiated value proposition if a one-time therapy can deliver sustained remission; however, cell therapy economics, manufacturing capacity, and vein-to-vein times remain gating factors for commercialization. Regulators will scrutinize durability beyond 24 weeks, infection burden associated with prolonged B-cell aplasia, and the generalizability of effect sizes inferred from named-patient experience.
The immediate milestone is interim Phase 2 data from KYSA-6, expected in the fourth quarter of 2025, which will set expectations for Phase 3 powering and endpoint durability. Key details to watch include subgroup consistency across antibody profiles, rescue medication rules, crossover timing, and hospitalization rates surrounding infusion and taper. On the CMC side, scalable autologous manufacturing, slot allocation, and product comparability as volumes rise will determine whether a favorable efficacy signal can translate into operational throughput. In SPS, regulatory openness to smaller, potentially nontraditional data packages could establish precedent for rare neuroautoimmune indications. The larger question is whether oncology-grade cell therapy infrastructure can be adapted quickly enough to support neurology trials at scale without creating new bottlenecks in site capacity and patient access.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
